The early detection of neurological diseases represents a major public health challenge. NeuroClues, a Franco-Belgian start-up, has obtained the CE marking, a significant milestone for its technological revolution. Its eye-tracking solution provides a rapid diagnosis for conditions such as Parkinson’s and Alzheimer’s.
The innovation announced at CES 2025 could transform the way healthcare professionals identify these disorders. Thanks to an interface paired with a headset, the technology quickly captures and analyzes eye movements, providing essential biomarkers within minutes. This significant progress holds promise for the early diagnosis of neurological disorders.
NeuroClues and the CE marking
The Franco-Belgian start-up NeuroClues has recently obtained the CE marking, a valuable certification that opens the doors to the European market. This regulatory advancement is the result of a rigorous compliance process with the European MDR (Medical Devices Regulation). With this recognition, NeuroClues can market its innovative eye-tracking solution aimed at the early detection of neurological disorders.
Eye-tracking technology
NeuroClues has developed a sophisticated device using artificial intelligence tools to analyze eye movements. Eye movements prove to be valuable indicators for identifying neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, and various myopathies. Analyzing the collected data allows for the extraction of relevant biomarkers within minutes, thereby facilitating a rapid diagnosis.
Features of the solution
The device consists of a headset using eye-tracking technology. This headset is capable of capturing up to 800 infrared images per eye per second. The generated data provides latency and auto-error measurements, which can be compared to healthy samples. This model is based on a leasing system, thus providing flexibility and accessibility to healthcare facilities.
Strategic partnerships
NeuroClues has established significant partnerships in Europe and the United States. In France, there is a concrete link with the Brain Institute, where several dozen patients with Parkinson’s are testing the prototype. <This partnership allows for validating and adapting the solution to real clinical needs, ensuring optimal efficiency. The start-up also collaborates with Dutch and American institutions, thus broadening its scope and prospects.
Experiments and clinical validation
Tests conducted at the Brain Institute are proving promising. Patients diagnosed with neurodegenerative diseases come to test the technology. These experiments allow for refining algorithms and optimizing the diagnostic process, contributing to better detection and management of the observed conditions.
Development perspectives
NeuroClues plans to develop databases in collaboration with the University of Siena, targeting various neurological diagnoses. With a recent fundraising of 5 million euros, the start-up aims to complete a Series A by the end of this semester. This funding, two-thirds of which is already committed, will accelerate the deployment of the solution in European hospitals and clinics.
Impact on early detection
The technology developed by NeuroClues could transform the landscape of neurological diagnostics. By enabling early diagnosis, it could change the lives of millions of patients potentially affected by diseases such as Parkinson’s, Alzheimer’s, and other similar conditions. Faster access to accurate diagnoses could also alleviate the economic burden placed on healthcare systems across Europe.
Frequently asked questions
What is the CE marking and why is it important for NeuroClues?
The CE marking certifies that the product meets European directives on safety and health. For NeuroClues, this means that their early detection technology for neurological diseases complies with European standards, thus allowing it to be marketed in Europe.
How does NeuroClues’ technology work to detect neurological diseases?
The technology uses eye movements to extract biomarkers. Using a headset equipped with infrared cameras, it records thousands of images per second to analyze latency and other indicators, thereby facilitating rapid diagnosis.
What types of neurological diseases can NeuroClues detect?
NeuroClues focuses on several neurological diseases, including Parkinson’s disease, Alzheimer’s disease, and various myopathies.
Where is NeuroClues’ technology currently being tested?
Currently, NeuroClues is conducting trials in partnership with the Brain Institute in France and collaborating with universities and institutions in the Netherlands and the United States, involving patients suffering from movement disorders.
What impact does early detection have on the treatment of neurological diseases?
Early detection allows for prompt intervention, which can improve patients’ quality of life and slow the progression of diseases like Parkinson’s and Alzheimer’s, thereby offering better treatment prospects.
What are the advantages of eye-tracking compared to traditional diagnostic methods?
Eye-tracking is non-invasive, quick, and can provide results within minutes, compared to longer and often more invasive diagnostic methods. It also allows for continuous monitoring of patients.
What are NeuroClues’ next goals after obtaining the CE marking?
NeuroClues plans to expand its deployment in hospitals and clinics across Europe while developing databases for various neurological disorders in collaboration with universities.
How does NeuroClues plan to finance its future development?
NeuroClues has recently raised 5 million euros and plans to finalize a Series A funding, with the majority of the funds already committed, to support the development and expansion of its technology.
What role does artificial intelligence play in NeuroClues’ technology?
Artificial intelligence is used to analyze eye data, allowing for the rapid identification of biomarkers associated with neurological diseases. This sophisticated analysis improves diagnostic accuracy.
